Compare Indivior Pharmaceuticals Inc. Common Stock (INDV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indivior Pharmaceuticals Inc. Common Stock vs BIO-TECHNE Corp — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.03B), while BIO-TECHNE Corp trades at $72.69 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 2.8× Indivior Pharmaceuticals Inc. Common Stock's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Indivior Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and BIO-TECHNE Corp for 64 Days on average.
| INDV | TECH | |
|---|---|---|
Market Cap | $4.03B | $11.37B |
Volume | 2,781,171 | 1,544,768 |
Sector | Health | Health |
52-Week High | $41.83 | $72.61 |
52-Week Low | $24.09 | $43.31 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $4.32B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bio-Techne (TECH) trades at $72.48, down 0.11% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average support. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. The company's pending acquisition by Merck KGaA for $73.00 per share, approved by shareholders (PRNewsWire, 2026-09-23), is a key near-term catalyst. Fundamentals indicate solid profitability with a 65.77% gross margin but elevated valuation ratios like a P/E of 62.52.
The outlook is dominated by the acquisition, offering a clear exit near the current price. Upside is capped by the deal price, while execution risks or regulatory hurdles pose downside. Analyst sentiment is neutral with a consensus hold rating. The stock presents a low-risk opportunity for merger arbitrage but limited growth potential for long-term investors absent competitive threats or integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Indivior Pharmaceuticals Inc. Common Stock
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
